CASE PRESENTATION
=================

A 68-year-old woman with an unremarkable medical history who had been diagnosed with B cell acute lymphocytic leukemia was admitted to the hematology clinic to undergo chemotherapy. Three days before admission, she developed cough, purulent sputum and dyspnea without fever. She had not been admitted to the hospital or have a history of antibiotic use within the previous three months.

On examination, her body temperature was 36°C, with a blood pressure of 105/50 mmHg, a heart rate of 80 beats/min, a respiratory rate of 30 breaths/min and oxygen saturation of 88% on room air. Breath sounds were coarse, with bilateral rales. Her physical examination was otherwise unremarkable. A computed tomography scan of her lungs revealed areas of consolidation suggesting pneumonia. On admission, she was started on intravenous piperacillin-tazobactam, 4.5 g every 6 h, ciprofloxacin, 400 mg every 12 h, as well as vincristine and prednisolone. Blood, urine and sputum cultures were negative.

On day 6, she became neutropenic. Hypoxemia, cough and sputum improved on day 14. Elevated C-reactive protein and procalcitonin levels decreased substantially. Antibiotics were discontinued. Meanwhile, treatment with imatinib was initiated.

On day 17, her initial symptoms recurred and a computed tomography scan revealed progression of previous consolidation areas. Serial serum galactomannan antigen tests were negative. Sputum cultures were obtained and piperacillin-tazobactam and ciprofloxacin were started again. Blood cultures were not repeated because the patient was afebrile.

Direct examination revealed good-quality sputum with dense, Gram-negative bacilli. After a 24 h incubation, nonfermenting Gram-negative bacilli grew in MacConkey agar. These colonies were identified as *Delftia acidovorans*, both by Vitek mass spectrometer (99% probability) (matrix-assisted laser desorption ionization time-of-flight \[Biomerieux, USA\]) and by the Vitek 2 System (98% probability) (Biomerieux, USA). The organism was susceptible to expanded- and broad-spectrum cephalosporins, carbapenems and piperacillin-tazobactam, but resistant to ampicillin-sulbactam, gentamycin, amikacin, ciprofloxacin and colistin.

On day 19 of admission, the patient was no longer neutropenic. Her symptoms resolved on day 24 and antibiotics were discontinued. The patient was discharged on day 27.

DISCUSSION
==========

*D acidovorans*, formerly known as *Comamonas acidovorans* or *Pseudomonas acidovorans*, is found in soil, water and the hospital environment. It can be isolated from the respiratory tract, the eyes and blood; however, it is rarely clinically significant ([@b1-cjidmm-26-277]).

We reported a *D acidovorans*-associated pneumonia in a neutropenic patient. One case involving pneumonia and bacteremia has been reported in the Turkish-language literature ([@b2-cjidmm-26-277]). Three cases involving pulmonary infections with *D acidovorans* have been reported in the English-language literature ([@b3-cjidmm-26-277]--[@b5-cjidmm-26-277]). Bacteremia associated with intravascular catheters ([@b6-cjidmm-26-277]--[@b11-cjidmm-26-277]) and endocarditis ([@b12-cjidmm-26-277],[@b13-cjidmm-26-277]) have been reported. Peritonitis ([@b14-cjidmm-26-277]), ocular infections ([@b15-cjidmm-26-277]--[@b17-cjidmm-26-277]) and urinary tract infection ([@b18-cjidmm-26-277]) have also been reported in the literature.

Three cases involving nosocomial pulmonary infections have been reported in the literature. Franzietti et al ([@b3-cjidmm-26-277]) reported an episode of nosocomial pneumonia as an opportunistic infection in a patient with AIDS. The organism was isolated from bronchoalveolar lavage fluid and the patient responded to ceftazidime treatment. Khan et al ([@b4-cjidmm-26-277]) reported a case involving a four-year-old immunocompetent child with empyema. *D acidovorans* was isolated from the drainage tube and the endotracheal aspirate sample. The patient did not survive, despite cefaperazone-sulbactam treatment. Chun et al ([@b5-cjidmm-26-277]) reported a chronic empyema case associated with *D acidovorans* in an immunocompetent adult patient.

Although rare, *D acidovorans* infection can be clinically important in immunocompromised patients with underlying malignancies, such as chronic kidney disease, HIV/AIDS ([@b2-cjidmm-26-277]) or patients taking immunosuppressive drugs. However, serious infections with *D acidovorans* have also been reported in immunocompetent patients ([@b4-cjidmm-26-277],[@b5-cjidmm-26-277],[@b18-cjidmm-26-277],[@b19-cjidmm-26-277],[@b20-cjidmm-26-277]).

The susceptibility profile of our isolate was similar to strains in previous reports ([@b10-cjidmm-26-277]--[@b13-cjidmm-26-277]).

Identification of the microorganism can be performed using a simple orange indole reaction test. With the addition of Kovac's reagent, the organism produces anthranilic acid using tryptophan. This results in a pumpkin-orange colour in the media, which is characteristic for *D acidovorans* ([@b4-cjidmm-26-277]).

An extensive literature search revealed several other cases of *D acidovorans* infection ([Table 1](#t1-cjidmm-26-277){ref-type="table"}).

Because of the ubiquitous presence of this microorganism, establishing its pathogenicity may be difficult. In the present case, clinical and radiological signs led us to a diagnosis of pneumonia, and the patient improved with antibiotic therapy. At that time, there was a large outbreak with carbapenem-resistant Enterobactericea in the medical and surgical intensive care units. We performed surveillance cultures in the hematology unit, and in the medical and surgical intensive care units. We did not isolate this microorganism from any environmental or patient cultures. Therefore, we accepted the organism as a pathogen in the present case.

A recent study performed in an intensive care unit in Brazil ([@b21-cjidmm-26-277]) showed clonal dissemination of *D acidovorans* in hospital settings using molecular confirmation. They isolated 24 *D acidovorans* strains in 21 patients from deep tracheal aspirate samples. However, they could not decide on the clinical significance of the pathogen due to lack of clinical data and patient follow-up.

*D acidovorans*-related infections are rare. It can occur in different age groups, as well as in both immunocompromised and immunocompetent patients ([@b3-cjidmm-26-277]--[@b14-cjidmm-26-277]). *D acidovorans* is often resistant to aminoglycosides ([@b20-cjidmm-26-277]), which are commonly used as empirical treatments in febrile neutropenic patients and in most Gram-negative infections. Therefore, timely identification of this organism to the species level is necessary to determine the most appropriate antibiotic therapy.
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###### 

Summary of *Delftia acidovorans* infections according to infection site

  **Reference**          **Age, years**   **Infection**                         **Risk factor(s)**                                     **Treatment**                                             **Outcome successful**
  ---------------------- ---------------- ------------------------------------- ------------------------------------------------------ --------------------------------------------------------- ------------------------
  Present case           68               Nosocomial pneumonia                  Hematological malignancy                               IV piperacillin/tazobactam                                Yes
  [@b2-cjidmm-26-277]    79               Nosocomial pneumonia and bacteremia   Chronic obstructive pulmonary disease                  IV meropenem                                              No
  [@b3-cjidmm-26-277]    Unknown          Nosocomial pneumonia                  AIDS                                                   IV ceftazidime                                            Yes
  [@b4-cjidmm-26-277]    4                Empyema                               Immunocompetent                                        IV cefaperazone/sulbactam                                 No
  [@b5-cjidmm-26-277]    5                Empyema                               Immunocompetent                                        IV imipenem                                               Yes
  [@b6-cjidmm-26-277]    11               CRBSI                                 Solid organ malignancy                                 Catheter removal and IV ceftazidime                       Yes
  [@b7-cjidmm-26-277]    Unknown          CRBSI                                 Hematologic malignancy                                 Unknown                                                   Yes
  [@b8-cjidmm-26-277]    4                CRBSI                                 Solid organ malignancy                                 IV ceftazidime                                            Yes
  [@b9-cjidmm-26-277]    27               CRBSI                                 AIDS                                                   Catheter removal, IV imipenem and amikacin                Yes
  [@b10-cjidmm-26-277]   65               CRBSI                                 Hematologic malignancy                                 Catheter removal and IV imipenem                          Yes
  [@b11-cjidmm-26-277]   10               CRBSI                                 End-stage renal disease and hemodialysis               Cahteter removal and IV cefepime                          Yes
  [@b12-cjidmm-26-277]   42               Infective endocarditis                Intravenous drug use                                   IV ceftazidime and ciprofloxacin                          No
  [@b13-cjidmm-26-277]   30               Infective endocarditis                Intravenous drug use                                   IV piperacillin/tazobactam                                Yes
  [@b14-cjidmm-26-277]   35               Peritonitis                           End-stage renal disease and peritoneal dialysis        IV ceftazidime, oral ciprofloxacin and catheter removal   Yes
  [@b15-cjidmm-26-277]   63               Keratitis                             Corticosteroid treatment and corneal transplantation   Topical and IV ceftazidime                                Yes
  [@b15-cjidmm-26-277]   49               Keratitis                             Corticosteroid treatment and corneal transplantation   Topical and IV ceftazidime                                No
  [@b16-cjidmm-26-277]   Unknown          Ocular infections                     Unknown                                                Unknown                                                   Unknown
  [@b17-cjidmm-26-277]   40               Keratitis                             Hyrdogel contact lenses                                IV gentamicin and ciprofloxacin                           Yes
  [@b18-cjidmm-26-277]   61               Urinary tract infection               Immunocompetent                                        Oral norfloxacin                                          Yes
  [@b19-cjidmm-26-277]   46               Bacteremia                            Immunocompetent                                        IV piperacillin/tazobactam                                Yes
  [@b22-cjidmm-26-277]   Unknown          Bacteremia                            Pressure-monitoring device                             Unknown                                                   Unknown
  [@b23-cjidmm-26-277]   93               Bacteremia                            Immunocompetent                                        IV imipenem/cilastatin                                    Yes
  [@b24-cjidmm-26-277]   30               Bacteremia                            Immunocompetent                                        IV piperacillin/tazobactam                                Yes

CRBSI Catheter-related bacteremia; IV Intravenous
